The estimated Net Worth of William Lis is at least $8.14 Milion dollars as of 1 July 2024. Mr. Lis owns over 10,397 units of Eidos Therapeutics Inc stock worth over $6,488,007 and over the last 11 years he sold EIDX stock worth over $1,101,070. In addition, he makes $553,909 as Independent Director at Eidos Therapeutics Inc.
William has made over 20 trades of the Eidos Therapeutics Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently he sold 10,397 units of EIDX stock worth $180,076 on 1 July 2024.
The largest trade he's ever made was exercising 269,299 units of Eidos Therapeutics Inc stock on 27 June 2017 worth over $2,243,261. On average, William trades about 16,332 units every 90 days since 2014. As of 1 July 2024 he still owns at least 53,089 units of Eidos Therapeutics Inc stock.
You can see the complete history of Mr. Lis stock trades at the bottom of the page.
William Lis serves as Independent Director of the Company. Mr. Lis has more than 28 years of biopharmaceutical experience. He also currently serves as executive chairman and interim chief executive officer of Jasper Therapeutics, Inc., which he led through a 2019 Series A financing. He served as chief executive officer and a director of Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) (“Portola”) from 2009 until 2018 after serving as chief operating officer and chief business officer in 2009 and 2008, respectively. Under his leadership, Portola grew from a discovery-stage company to a fully integrated R&D and commercial organization, and independently discovered and developed Andexxa® and evyxxa® through commercial launch, and advanced cerdulatinib into clinical development. He led corporate partnerships and private and public financings including an initial public offering in 2013. Prior to that, Mr. Lis held executive and management positions at Scios, Inc. (a Johnson & Johnson company), where he last served as senior vice president of business and new product development, having led efforts for the in-licensing, development and commercial launch for Xarelto®. He also held positions of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) and Rhone Poulenc Rorer in sales, marketing, medical affairs and business development. He was involved in the U.S. commercial launch of several products, including Integrilin®, Lovenox® and Rilutek®. Mr. Lis serves as independent director for Zai Lab Limited (Nasdaq: ZLAB) and served as a member of the Biotechnology Innovation Organization (BIO) board of directors for the Emerging Companies Section in 2015 and 2016. Mr. Lis holds a B.S. from the University of Maryland. Mr. Lis is qualified to serve on our Board of Directors because of his extensive leadership and financial experience in the biopharmaceutical industry.
As the Independent Director of Eidos Therapeutics Inc, the total compensation of William Lis at Eidos Therapeutics Inc is $553,909. There are 1 executives at Eidos Therapeutics Inc getting paid more, with Cameron Turtle having the highest compensation of $578,400.
William Lis is 55, he's been the Independent Director of Eidos Therapeutics Inc since 2018. There are 2 older and 5 younger executives at Eidos Therapeutics Inc. The oldest executive at Eidos Therapeutics Inc is Uma Sinha, 63, who is the Chief Scientific Officer, Director.
William's mailing address filed with the SEC is C/O ZAI LAB LIMITED, 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE, MA, 02142.
Over the last 6 years, insiders at Eidos Therapeutics Inc have traded over $18,169,563 worth of Eidos Therapeutics Inc stock and bought 30,345,136 units worth $349,599,962 . The most active insiders traders include Capital Management, L.P.Ra ..., Pharma, Inc. Bridge Bio a Rajeev M. Shah. On average, Eidos Therapeutics Inc executives and independent directors trade stock every 13 days with the average trade being worth of $52,576,942. The most recent stock trade was executed by Pharma, Inc. Bridge Bio on 26 January 2021, trading 14,428,836 units of EIDX stock currently worth $1,763,348,048.
Eidos Therapeutics Inc executives and other stock owners filed with the SEC include: